Five Things to Know About Esketamine
In March 2019, intranasal esketamine—a form of ketamine marketed as SPRAVATO™ CIII Nasal Spray*—was approved by the U.S. Food and Drug Administration (FDA) to treat patients with treatment-resistant depression (TRD). James Murrough, MD, PhD, Director of Mount Sinai’s...
Partnering With the Community to Bring Mental Health Services to Those in Need
On Saturdays during the month of February, a group of organizations that support the homeless known as the Rescue Alliance, including Salvation Army, The Bowery Mission, Hope For New York, and New York City Relief, host an annual service event called Don’t Walk By....
Inventing New Ways to Deliver Mental Health Care to the Community
As part of the state’s ongoing effort to further innovate in behavioral health care and develop more effective alternatives to emergency rooms, the New York State Office of Mental Health (OMH) asked Mount Sinai Morningside (formerly known as Mount Sinai St. Luke’s) to...
What Are the Benefits of CBD?
Interest in cannabidiol (CBD) has increased dramatically in recent years. Available in oils, lotions, and vaping fluid, the substance has been touted as a cure-all for various ailments including anxiety, arthritis, and insomnia. While its growing reputation is...
Five Things to Know About MDMA-Assisted Psychotherapy for PTSD
MDMA, the psychoactive drug sometimes known as ecstasy, is poised to become a powerful tool in the treatment of PTSD. In 2017, the U.S. Food and Drug Administration (FDA) designated MDMA-assisted psychotherapy as a breakthrough therapy. Although MDMA itself is not...
Confronting Addiction: Science, Policy, and Care
Luminaries in addiction research, policy, and clinical care, led by keynote speaker Nora Volkow, MD, Director of the National Institute on Drug Abuse (NIDA), participated in an all-day conference in the fall hosted by the Addiction Institute of...